Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...

As of Wednesday, February 25, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 11.19%, which has investors ...

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the ...

(RXRX) on Wednesday reported a loss of $108.1 million in its fourth quarter. The Salt Lake City-based company said it had ...

Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion ...

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...